Challenging the Frontiers in Healthcare



MACLEOD?

Pharmaceuticals Limited Mumbai, INDIA





Macleods Overview

9th ranked Pharmaceutical Company in India *(IMS-ORG April'14)

Vertically Integrated Pharmaceutical Company Developing & Manufacturing APIs & Finished Dosage Forms

- 11 Finished Dosage Manufacturing Facilities
- One API Manufacturing Site 4 Manufacturing Facilities
- Supported by state- of-the- art R&D Centre & In- House Bioequivalence Centre

Over 10,000 employees are at service to provide uninterrupted care

Annual turnover of US\$ 557 million (2014-2015)

Presence in more than 100 countries

Milestones



1985

Incorporation

1992

• Started new facility at Palghar

2000

• Started new facility at Daman

2003

Established New R&D Facility

2005

• Established CRO in Mumbai

2007

- UKMHRA Approval of FDF Oral Dosage facility located at Daman
- Established new API Manufacturing Facility & became vertically integrated
- Became one of the top 25 Indian Pharma Companies

2008

- USFDA Approval of FDF Oral Dosage facility
- Established New FDF facility in Baddi (North India)
- CRO Facility Approved by USFDA

2009

Clinical Facility Approved by ANVISA Brazil

2011

API facility approved by US FDA

2012


• Launched own operations in USA

2013

• Launched own operations in South Africa



2013-14 Sales





Dossiers & Approvals

API DMF / CEP Application

- US:- Filed 48 API DMFs, Target to file 10-15 APIs every year
- EU :- CEP application: 11 APIs and Received: 9 CEP approval

USA Filing

- Filed **93** ANDAs, Received **18** approvals
- Target to file 20 ANDAs every year

Europe Filing

- 17 DCPs and Received 13 MA's mainly in UK, Germany, Spain and Italy
- Macleods has over **1,500** registrations across the globe



Wings across the globe....

Presence in more than 100 countries

Subsidiaries in 6 Countries

USA, UK, South Africa, Ukraine, Peru, Kazakhstan Various Business Models

Private Market

Licensing and Formulation Supply

Technology Transfer with API supply

API Supply

Joint Venture

Tenders

Presence in regulated market

USA,

CIS,

Germany,

Spain,

Italy,


UK,

Romania,

Serbia & many more


Presence in Various Therapies







Finished Dosage







Manufacturing Facilities






1 Formulation Facility-Sikkim (Under Construction)

4 Formulation Facilities-Daman

 API Facility-Sarigam

R & D & Corporate Office- Mumbai





FDF* Quality Achievements













and many others...

FDF: Finished Dosage Form

Formulation Facility Daman





Approved by USFDA, UKMHRA, WHO Geneva, ANVISA Brazil, MCC South Africa,TGA Australia, SSMMD Ukraine & many other regulatory agencies.

Formulation Facility Baddi





Approved by USFDA, UKMHRA, WHO Geneva, MCAZ Zimbabwe, MCC South Africa, Saudi Arabia & many other Regulatory Agencies.





Formulations	Per Year
Tablets	7,750 Million
Capsules	500 Million
Injectables	55 Million
Granules	60,000 Kg
Dry Powder for Injection	34 Million
Soft gels	175 Million
Liquids	28 Million
DPI	2 Million
MDI	2 Million



API Facility



API Quality Achievements











and many others...

API Facility Sarigam


















Equipment Name	Number
Glass Line Reactor	38
Stainless Steel Reactor	37
Centrifuge	43
Vacuum Tray Dryer	18
Tray Dryer	13
Rotary cone dryers	11
Fluid Bed Dryers	5
Multi mills	17
Vibro sifters	14
Jet Mill	13
Blender	4
Agitated Nutch filter	2







R & D Center Various Departments



Chemical Research Department

• 30 Work Stations. Out put: 10-15 DMF/ Year

Analytical Research Department

- API and Finished Dosage development is supported by various instruments such
 - 100 HPLC
 - 12 LCMS
 - XRD
 - Mass spectrometer
 - Particle Size Analyzer
 - Water Content Analyzer

Formulation Development Department

- Well equipped to develop new FDF
- Output: 10-15 Dossiers/ Year.

MACLEOD?

R & D Center | Various Departments

Regulatory Department

- In- house well experienced regulatory team of more than 40 people.
- Responsible for dossier filings, query responses, approvals & renewals.

Intellectual Property Rights Department


- In-house team of **15** people
- · Provide technical guidance on IP
- Decide strategy/process/formula for API & Finished Dosage development

Stability Section (Part of Analytical Research Department)

- All APIs & FDF developed in R & D are charged on to the following Stability conditions.
- Walk in Chambers: 40 C/ 75%RH, 25 C/ 60%RH, 30 C/ 65%RH



Bio-Equivalence Center



In-House Bio-Equivalence **Centre**



BE center has

• 184 Beds in 4 CPUs

GLP &GCP Approval from

- USFDA
- MCC South Africa
- WHO Geneva
- UK MHRA
- MOH Thailand
- MOH UAE

In-House Bioequivalence Center



184 Beds. Approved by USFDA, MCC South Africa, WHO Geneva & MOH UAE.

THANK YOU